Four SPORE Grants Will Support Ovarian Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

BETHESDA, Md-Four institutions have received SPORE (Specialized Program of Research Excellence) grants from the NCI for ovarian cancer research. The grants, totaling $5.85 million for the first year, went to:

BETHESDA, Md—Four institutions have received SPORE (Specialized Program of Research Excellence) grants from the NCI for ovarian cancer research. The grants, totaling $5.85 million for the first year, went to:

The University of Texas M.D. An-derson Cancer Center, to pursue chemo-prevention, antiangiogenesis, and novel treatments for the disease.

Fred Hutchinson Cancer Research Center, to establish the Pacific Ovarian Cancer Research Consortium, whose efforts will include studies of genes responsible for resistance to chemotherapy and the development of a nucleic acid vaccine for prevention of the disease.

Fox Chase Cancer Center, to develop an interdisciplinary ovarian cancer program focused on carcinogenesis, prevention, and treatment of the cancer.

The University of Alabama at Birmingham, for the development of a new genetically engineered monoclonal antibody therapy, targeted immunotherapy, and research to find markers of disease progression that can be used as targets for chemoprevention.

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.